9:24 - 5:40 EDT | 6:25 - 2:40 PDT

8:30 am Online Registration & Virtual Coffee Networking

8:55 am Chair’s Opening Remarks

Exploring Allogeneic NK Cell Therapies

9:00 am Development of Allogeneic NK Cell Therapeutics Using T Cell-based Feeder System


  • Outlining an engineered T cell as a new feeder system for NK cell activation and expansion
  • Discussing characteristics of NK cell expansion profile using e-Feeder system
  • Covering clinical trials of expanded, activated allogeneic
  • NK cells by large-scale production
  • Development of gene-modified NK cell
  • Discussing technical issues for CAR-NKs

9:30 am Incorporating Novel Tools to Enhance NK Cell Manufacturing


  • Outlining current manufacturing challenges for scaling up NK cell manufacturing
  • Converting to a feeder-free expansion platform using Cloudz NK Expansion Kit
    and ExCellerate NK Cell Expansion Media
  • Streamlining cytokine supplementation into closed system manufacturing using
    GMP ProDots Proteins

10:00 am Optimizing NK Cell Therapy: Endogenous Stimulation, Single Donor Infusions & Off-the-Shelf Products


  • Understanding the biology and activity of IL-15 therapy
  • Furthering the understanding of the fundamental biology of immune engagement
    of endogenous NK cells
  • Covering the history of single related donor products
  • Deliberating the future of off-the-shelf gene edited iPSC derived NK cells in the
    clinic and in development

10:30 am An Off-the-Shelf, GMP Compliant, Fully Closed & Semi-Automated Large-Scale Production System for Allogeneic NK Cells


  • With the highly unmet need to treat large cohort of patients and with multiple doses, a true off the shelf approach is the only way
  • Glycostem began to envision this, by setting up a world’s first completely closed manufacturing platform for allogeneic NK cells (oNKord®) from fresh umbilical cord blood stem cells
  • Optimised freezing and thawing conditions, which result in high recovery and product functionality, enabled cell banking of multiple infusion doses produced from one manufacturing batch
  • NK cells by large-scale production
  • Development of gene-modified NK cell
  • Setting up of a completely closed system faces many challenges, and during this journey over the last two years, Glycostem has successfully resolved several bottlenecks and worked closely with the regulatory authorities in achieving an “universal off the shelf” NK cell therapy product

11:00 am HLA-E & NK Cell Education as Major Determinants of Anti-tumor Function

  • Amir Horowitz Professor, Icahn School of Medicine at Mount Sinai


• Genetic variation in HLA class I and KIR genes defines the phenotypes and functions of NK cells found in the circulation and tissues.
• HLA-E is a strongly inhibitory receptor that signals through NKG2A-expressing NK cells and CD8 T cells. HLA-E expression is highly variable and correlates with prognosis across numerous cancers as well as predicts tumor response to multiple immunotherapies.
• Highlighting ex vivo profiling data of the tumor microenvironment in patients with bladder, kidney and prostate cancer using Olink proteomics, CyTOF, and imaging mass cytometry
• Report on in vitro mechanistic studies using antibodies targeting NKG2A and KIR as well as oncolytic viruses that suppress HLA-C and HLA-E as strategies for harnessing ‘educated’ NK cells in cancer immunotherapies

11:30 am Virtual Speed Networking & Morning Break

Research & Development

Manufacturing & Commercialization

Discussing NK Cell Memory

Manufacturing Considerations for Allogeneic NK Cell Therapies

12.10 Memory-like NK Cell Translation as Cancer Immunotherapy

• How IL-12/15/18 activated NK cells differentiate into memory like NK cells
• Outlining enhanced preclinical anti-tumor properties of memory-like NK cells
• Examination of the first-in-human studies that have demonstrated safety and preliminary activity of memorylike NK cells for patients with relapsed/refractory AML
• Immune-compatible use of memory-like NK cell therapy in clinical trials results in prolonged persistence following a single treatment
• How are memory-like NK cells a platform for ongoing innovation as cancer therapy, including targeting with monoclonal antibodies and engineering with CAR

Todd Fehniger, Associate Professor of Medicine, Washington University School of Medicine

12.10 Validation & Implementation of a Universal Donor Algorithm for Generating an Off-the-Shelf NK Cell Therapeutic

• Describing genetic variability of human NK cells and their impact on function
• Understanding the rationale for a Universal Donor algorithm
• Interpreting the preclinical data supporting a Universal Donor algorithm
• Describing the logistics in place for donor selection and manufacturing of a Universal Donor off-the-shelf NK cell therapeutic

Dean Lee, Director, Cellular Therapy and Cancer Immunotherapy, Nationwide Children’s Hospital

12.35 NK Cell Transduction & CAR-NK Cells

• Highlighting how baboon envelope pseudotyped lentiviral vectors (BaEV-LVs) outperform other viral vectors for NKcell transduction, both for freshly isolated and amplified NKcells, regardless of expansion method
• Outlining that BaEV-LV-based transduction allows for a stable and efficient CAR expression by NK cells.
• Examining how CAR-NK cells keep their natural cytotoxic function while being more efficient at antigen-bearing killing tumor cells
• Covering how NK cells can be transduced to express two CARs at their surface
• Revealing that modification of CAR-tail has an effect on the efficacy of CAR-NK cells killing capacity

Elie Haddad, Professor of Pediatrics, University of Montreal

12.35 Strategies to Improve NK Cell-Mediated Therapies

• Discussing the use of human pluripotent stem cells to produce standardize NK cells
• Highlighting strategies to engineer iPSC-derived NK cells to improve anti-tumor activity
• Examining screening strategies to identify novel NK cell targets

Dan Kaufman, Professor, UCSD

1:00 pm Virtual Speed Networking & Lunch Break

2.00 Advancing Kiadis NK Cell Therapeutics: the K-NK Platform

• mbIL21 platform for production and delivery of clinical NK cell therapeutic

• Clinical advancement with the mbIL21 stimulated NK cells

• Exploring the Kiadis vision for immunotherapy

Robert Igarashi, VP, Discovery & Pre-Clinical Development, Kiadis Pharma

2.00 Streamlining Clinical Trials: Applying Rigor in
Flow Cytometry to Facilitate Therapeutic Developments

• Characterization of the immune response by flow cytometry provides knowledge of cellular phenotype and function supporting the development of therapies that beneficially modulate the immune response
• Lack of reproducible data, often related to workflow inconsistencies and reagent integrity, sample prep, data acquisition and data analyses, is a critical challenge in flow cytometry
• These inconsistencies can result in the generation of erroneous biologically relevant data, having direct implications on therapeutic development
• This session provides information and practical solutions on streamlining the workflow to empower the generation of standardized and  reproducible flow data specifically in the field of clinical research; starting from sample prep to data analysis

Alina Lelic, Field Marketing Manager, Flow Cytometry, Beckman Coulter Life Sciences

2.25 Human IL-15 Transgenic NSG (NSG-Tg(Hu-IL15)) Mice, Enhance Differentiation of Functional Human Natural Killer Cells

• Hemizygous NSG-Tg(Hu-IL15) mice express a physiological level of human IL15 (7.1 +/- 0.3 pg/ml)

• NSG mice irradiated and injected with CD34+ human stems cells (HSC) develop significantly higher levels of functional human CD56+ NK cells in peripheral blood, spleen and bone marrow than NSG controls

• HSC humanized NSG-Tg(Hu-IL15) mice exhibit physiological levels of human NK cells in peripheral blood with corresponding phenotypic markers

• Human NK cells in HSC humanized NSG-Tg(Hu-IL15) exert in vitro and in vivo antitumor activity

Basille Siewe, Director of Business Development, The Jackson Laboratory

2.25 Development & Manufacture of Chimeric Antigen Receptor-Engineered Allogeneic γδ T Cell Therapies

• Hearing rationale and preclinical evidence for CAR γδ T cell therapies in solid tumors and hematologic malignancies
• Clinical-scale, cGMP-compliant manufacturing considerations of γδ T therapies
• Discussing off-the-shelf cell banks and clinical application

Stewart Abbot, CSO, Adicet Bio

2.50 Live Discussion & Q&A

Todd Fehniger, Associate Professor of Medicine, Washington University School of Medicine
Elie Haddad, Professor of Pediatrics, University of Montreal
Robert Igarashi, VP, Discovery & Pre-Clinical Development, Kiadis Pharma
Basile Siewe, Director of Business Development, The Jackson Laboratory

2.50 Live Discussion & Q&A

Dean Lee, Director, Cellular Therapy & Cancer Immunotherapy, Nationwide Children’s Hospital
Alina Lelic
, Field Marketing Manager, Flow Cytometry, Beckman Coulter Life Sciences
Stewart Abbot
, CSO, Adicet Bio

3:10 pm Virtual Demo & Q&A with Partners


Visit the virtual exhibition area to explore the services and solutions our specialist vendors have to offer

3:40 pm Mechanisms Governing the Selection & Expansion of CD8+ T Cells by SuperCharged NK Cells from Human Donors & Humanized Mice


• Covering differential roles of Dendritic cells and Osteoclasts in expansion of T cells and NK cells respectively
• Outlining mechanisms governing decreased expansion of super-charged NK cells from cancer patients
• Discussing mechanisms underlying the inability of patients’ NK cells to
be super-charged, forming the basis for the selection of allogeneic vs. autologous NK cells for cancer immunotherapy
• Understanding mechanisms underlying CD8+ T cell expansion by supercharged NK cells and their functional activation
• Analyzing studies of NK cells from cancer patients and tumor bearing hu-BLT mice

4:10 pm A Novel First in Class ex vivo Combination Between NK cells & a CD38 Targeting Antibody Recruiting Molecule as a Novel Approach to Arm NK Cells Without Cellular Engineering for the Treatment of Multiple Myeloma


• Kleo has developed Antibody Recruiting Molecule as a novel chemical platform to target NK cells without cellular engineering relies
• ARM are synthetic, bifunctional molecules that bind to a target, e.g. tumor antigen like CD38 or viral antigen like Sars-Cov2 Spike protein, and simultaneously recruit endogenous IgG harnessing FcR dependent effector cells including NK cells
• Combining ARM molecules and NK cells ex vivo before injection into a patient, results in the creation of CAR-like construct that can arm the NK cells to more efficiently kill the targeted tumor cells, therefore the same clinically validated NK cell therapy can now be used with several different ARMs to optimally target many different diseases

4:40 pm Targeting NK Cells at Different Stages of the Cancer Immunity Cycle: Checkpoints & Next Generation NK Cell Therapies


• Discussing NK cells’ control of metastasis
• Highlighting NK cells driving tumor inflammation
• NK cells potentiating immune checkpoint blockade response
• Emerging activation checkpoint in NK cells
• Strategies to target tumor resident NK cells

5:10 pm End of Conference Day One